Modification of natural tryptamines for the treatment of neuropsychiatric diseases
Journal of Psychopharmacology October 4, 2025 Michael G. Palfreyman, Geoffrey B. Varty, Erik M. Stang et al. 3 citations
The last decade represented a period of unprecedented interest in, and development of, traditional psychedelic substances for the treatment of a variety of neuropsychiatric disorders. While early clinical trials of classical psychedelics, several of the major ones being tryptamines, have demonstrated robust efficacy in patients with minimal adverse effects, many of these molecules have...